| Entries |
| Document | Title | Date |
|---|
| 20080199535 | Compositions Having a High Antiviral and Antibacterial Efficacy - Antimicrobial compositions having a rapid antiviral and antibacterial effectiveness, and a persistent antiviral effectiveness, are disclosed. The antimicrobial compositions contain (a) an antimicrobial agent, (b) a disinfecting alcohol, and (c) (i) an organic acid, (ii) an inorganic salt comprising a cation having a valence of 2, 3, or 4 and a counterion capable of lowering a surface pH to about 5 or less, (iii) an aluminum, zirconium, or aluminum-zirconium complex, or (iv) mixtures thereof, wherein the composition has a pH of about 5 or less. | 08-21-2008 |
| 20080206356 | Pharmaceutical Compositions for the Treatment of Neurodegenerative Disorders - Pharmaceutical compositions comprising an effective amount of a tungsten (VI) compound, preferably of a tungstate salt, and more preferably of sodium tungstate (Na | 08-28-2008 |
| 20090017133 | PHARMACEUTICAL FORMULATION COMPRISING LANTHANUM COMPOUNDS - This invention relates to a chewable lanthanum formulation comprising a pharmaceutically effective amount of a lanthanum compound; and at least one chewable pharmaceutically acceptable excipient. This invention also relates to a pharmaceutical formulation in a tablet or in a powder comprising a pharmaceutically effective amount of a lanthanum compound produced by a process which comprises the steps of (a) powder blending the lanthanum compound and at least one pharmaceutically acceptable excipient in a mixer to form a mixture; or (b) powder blending the lanthanum compound and excipients, compressing the resulting combination into a slug material or roller compacting the resulting combination into a strand material, and milling the prepared material into a free flowing mixture; and (c) compressing the resulting mixture into a tablet or filling up the resulting mixture in an appropriate container. | 01-15-2009 |
| 20090028961 | Decontamination solution and its use for denaturation, modification, degradation, solubilisation and removal of proteins, nucleic acid molecules and microorganisms - The invention concerns a three component system comprising surface-active substances, vitamins and metal ions for efficient destruction and removal of contaminating proteins, nucleic acids and microorganisms from surfaces like for example laboratory benches, floors, equipment and instruments. These non-corrosive and non-toxic solutions for removal of proteins, nucleic acids and microorganisms are applied by spraying, rubbing or immersion of contaminated surfaces thereby destroying, solubilizing inactivating and removing proteins and nucleic acids. In that way also microorganisms are killed with high efficiency and at the same time all genetic information is inactivated. | 01-29-2009 |
| 20090053322 | RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water. | 02-26-2009 |
| 20090061020 | Brimonidine Compositions for Treating Erythema - The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a patient with rosacea by administering the composition of the invention to the site of erythema on the skin of the patient. | 03-05-2009 |
| 20090123562 | Pharmaceutical Formulations of Gallium Salts - The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents. | 05-14-2009 |
| 20090130225 | MACROLIDES DERIVATIVES AS ANTIBACTERIAL AGENTS - The present invention provides macrolide derivatives, which can be used as antibacterial agents. Compounds described herein can be used for treating or preventing conditions caused by or contributed to by gram-positive, gram-negative or anaerobic bacteria, more particularly against, for example, Staphylococci, Streptococci, Enterococci, | 05-21-2009 |
| 20090130226 | METHOD OF PRODUCING BIOMATERIALS AND BIOMATERIALS PRODUCED BY THE SAME - A biomaterial producing method and a biomaterial produced by the same are disclosed. The method includes preparing an electrolyte by dissolving monobasic potassium phosphate (KH | 05-21-2009 |
| 20090191280 | HARD TISSUE REPAIRING MATERIAL - A hard tissue repairing material includes zirconia as a base material. A surface of the base material has a hydrophilic group. The hydrophilic group is bonded to zirconium atom in the base material. The base material may contain at least an ionic component that is selected from a group consisting of calcium ion, sodium ion, potassium ion, and phosphate ions within the surface. A hard tissue repairing material may include zirconia as a base material and a layer of a main component of an apatite. The layer of the apatite may be formed on a hydrophilic group bonded to zirconium atom in the base material. | 07-30-2009 |
| 20090263502 | Highly Dispersible Titanium Dioxide Powder - Provided is a means for controlling a plant disease or a pest insect by utilizing a highly dispersible titanium dioxide powder produced by a discharge treatment of a titanium dioxide powder. Titanium dioxide is a substance which is highly safe to living organisms and the environment. A plant disease or a pest insect can be controlled by utilizing the substance without adversely affecting the environment. | 10-22-2009 |
| 20090269418 | Compositions and Methods for Inducing Hair Growth - Novel therapeutic methods and pharmaceutical compositions utilizing tellurium-containing compounds for inducing hair growth for the treatment of various types of alopecia and other conditions associated with hair loss. | 10-29-2009 |
| 20090280189 | System for the liberation of an active principle and its use - A local system for the liberation of an active principle is described which consists of spherical bodies which are composed of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate and, if necessary, zirconium dioxide and/or barium sulphate and a pharmaceutical active principle, which contains at least one hemostyptically effective compound stable at least up to 120° C., preferably a calcium salt. The local system for the liberation of an active principle is provided as medical product or drug. | 11-12-2009 |
| 20100015246 | COMBINATION OF A LANTHANUM COMPOUND AND BONE ENHANCING AGENT FOR THE TREATMENT OF BONE DISEASES - The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and/or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound and a bone enhancing agent, such as vitamin D. | 01-21-2010 |
| 20100034899 | USE OF ONE OR MORE OF THE ELEMENTS FROM THE GROUP YTTRIUM, NEODYMIUM AND ZIRCONIUM, AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN THOSE ELEMENTS - A method of treating a patient includes the medical use of one or more of the elements from the group yttrium, neodymium and zirconium, pharmaceutical formulations which contain said elements and implants which are at least region-wise made up of such formulations. It has been found inter alia that a formulation containing one or more of the elements has an action of inhibiting the proliferation of human smooth muscle cells. | 02-11-2010 |
| 20100092576 | PHARMACEUTICAL COMPOSITIONS CONTAINING LANTHANUM HYDROXYCARBONATE - An assay for analytically determining the amount of an impurity in a solid sample is provided. This X-ray diffraction method preferably uses the Rietveld refinement. | 04-15-2010 |
| 20100239687 | USES OF RARE EARTH ELEMENTS FOR SLIMMING - Disclosed is a use of rare earth element selected from the group consisting of lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu), scandium (Sc) and yttrium (Y), and a mixture thereof, or a salt or an oxide, for promoting lipidolysis, anti-cellulite, enhancing skin firmness, or for slimming. | 09-23-2010 |
| 20100247674 | MAGNOTHERAPY PRODUCTS - The present invention relates to the use of magnets in the treatment of cancer wherein the magnetic product comprises a magnet having positive and negative poles, the magnet having an additional metallic directional which distorts the magnetic field distribution around the magnet so as to attenuate the magnetic field in the vicinity of the positive pole of the magnet. The invention also relates to methods of treatment using those magnets. | 09-30-2010 |
| 20100247675 | MAGNOTHERAPY PRODUCTS - The present invention relates to a method of treating and/or reducing and/or preventing symptoms associated with menopause comprising applying a magnetic product to a human or animal body wherein the magnetic product comprises a magnet having positive and negative poles, the magnet having a metallic element which distorts the magnetic field distribution around the magnet so as to attenuate the magnetic field in the vicinity of the positive pole of the magnet. The invention also relates to the use of a magnetic product in the prevention and/or treatment of cancer, wherein the magnetic product comprises a magnet having positive and negative poles, the magnet having a metallic element which distorts the magnetic field distribution around the magnet so as to attenuate the magnetic field in the vicinity of the positive pole of the magnet. The invention also relates to the use of a magnetic product to increase the level of IGHBP-3 in a subject, in which the magnetic product comprises a magnet having positive and negative poles, the magnet having a metallic element which distorts the magnetic field distribution around the magnet so as to attenuate the magnetic field in the vicinity of the positive pole of the magnet. | 09-30-2010 |
| 20100291233 | TREATMENT OF NEUROLOGICAL DISORDERS - This invention relates to the use of selenate or a pharmaceutically acceptable salt thereof in methods and compositions of treating or preventing non-tauopathy neurological disorders. In some embodiments, the invention relates to the use of selenate or a pharmaceutically acceptable salt thereof in combination with other therapies for use in methods of treating or preventing non-tauopathy neurological disorders. | 11-18-2010 |
| 20110020467 | Inhibition of Biogenic Sulfide Production Via Biocide and Metabolic Inhibitor Combination - Biogenic sulfide production is synergistically inhibited by treating sulfate-reducing bacteria (SRB) with a biocide and a metabolic inhibitor. The biocide directly kills a first portion of the SRB. The metabolic inhibitor inhibits sulfate-reducing growth of a second portion of the SRB without directly killing the second portion of the SRB. The treatment of SRB with both a biocide and a metabolic inhibitor provides effective biogenic sulfide inhibition at significantly lower concentrations than would be required if the biocide or metabolic inhibitor was used alone. | 01-27-2011 |
| 20110104301 | METHODS OF REDUCING PAIN AND INFLAMMATION - Provided herein are methods of treating or preventing pain and/or inflammation in a subject comprising administering to the subject a transient receptor potential (TRP) ion channel inhibitor. | 05-05-2011 |
| 20110111054 | BMP-7 FOR USE IN TREATING VASCULAR SCLEROSIS - The present invention relates to prevention and treatment of vascular sclerosis, vascular calcification (VC) and neointimal hyperplasia using a morphogen. | 05-12-2011 |
| 20110151018 | METHODS OF INSECT CONTROL - The present invention is directed towards methods of inhibiting thermo- and chemo-sensing in insects and pests by inhibiting TRPA1 ion gated channel or family members. The present invention is also directed towards methods of insect control by modulating the TRPA1 ion gated channel or family members. The methods are applicable to a wide variety of insects and pests including agricultural and horticultural pests. | 06-23-2011 |
| 20110151019 | Heat Generating Nanomaterials - The present invention relates to a heat-generating composition, comprising a hetero-structure nanomaterial which comprises (a) a first material comprising at least one component selected from the group consisting of a metal, a metal chalcogen, a metal pnicogen, an alloy and a multi-component hybrid structure thereof; and (b) a second material comprising at least one component selected from the group consisting of metal, metal chalcogen, metal pnicogen, alloy and the multi-component hybrid structure thereof; wherein the first material is enclosed in the second material; wherein at least one of the first material and the second material comprise a magnetic material. The specific loss power of the present nanomaterial is much higher than that of conventional nanomaterials (e.g., 40-fold higher than commercially accessible Feridex) and may be controlled by changing compositions or ratios of the first material and/or the second material. The heat-generating nanomaterial of the present invention may be used in a variety of application fields, for example cancer hyperthermia. | 06-23-2011 |
| 20110165262 | REDUCING DRUG DEPENDENCE OR ADDICTION - Drug dependence or drug addiction is reduced by the administration to a subject of one or more of the following components: an antioxidant; vitamin B; a metal salt that provides metal ions, in vivo; insulin or a growth hormone; an antihistamine; and a herbal extract. | 07-07-2011 |
| 20110171320 | Methods to extend vision to infrared wavelengths - In a method for visualizing an object under conditions of low ambient light, the object to be visualized is exposed to incident electromagnetic radiation having a wavelength greater than what can normally be seen by the naked eye. Light reflected from the object is then perceived with an enhanced eye. The enhanced eye contains an up-conversion material optically coupled to the photoreceptors. Up-conversion materials absorb in the infrared and luminesce in the visible. Particles containing such materials are delivered to the eye where they are optically coupled to the retina or photoreceptor cells and nearby tissues. There they provide in-situ up-conversion of infrared frequencies (from about 700 to about 11,000 nm) to the otherwise unaided eye. | 07-14-2011 |
| 20110274767 | PRODUCTION METHOD OF TITANIUM OXIDE SOL - There is provided a method for efficiently producing an anatase-type titanium oxide sol in an extremely advantageous dispersion state. The method comprises mixing a titanium alkoxide, an organic acid, and a quaternary ammonium hydroxide with water in a molar ratio of the organic acid of 0.4 to 4.0 relative to 1 mol of a titanium atom of the titanium alkoxide and in a molar ratio of the quaternary ammonium hydroxide of 0.8 to 1.9 relative to 1 mol of the organic acid to prepare an aqueous mixed solution having a concentration in terms of TiO | 11-10-2011 |
| 20110280956 | LANTHANUM CARBONATE HYDROXIDE, LANTHANUM OXYCARBONATE AND METHODS OF THEIR MANUFACTURE AND USE - The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia. | 11-17-2011 |
| 20120015045 | FUNCTIONALIZED FULLERENES AS ANTIFUNGAL AGENTS - Functionalized fullerenes are used in a method of combating fungal growth on surfaces and treating fungal diseases of patients. Surfaces that can be treated by the materials comprising an effective amount of functionalized fullerenes include those of fruits, vegetables, harvested grains, plants, or plant seeds. The method of combating fungal growth on a surface can be augmented but is not dependent on irradiation of the surface by light. Functional fullerenes are employed in various dosage forms such as topical, ingestible or administration. | 01-19-2012 |
| 20120040016 | BRIMONIDINE COMPOSITIONS FOR TREATING ERYTHEMA - The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a patient with rosacea by administering the composition of the invention to the site of erythema on the skin of the patient. | 02-16-2012 |
| 20120058200 | PROCESS FOR THE PREPARATION OF LANTHANUM CARBONATE DIHYDRATE - Present invention relates to a process for the preparation and pharmaceutical usage of dihydrate form of lanthanum carbonate. Present process produces lanthanum carbonate dihydrate (La2(CO3)3.2H2O) free of lanthanum hydroxycarbonate and is stable at ambient condition. Lanthanum carbonate dihydrate exhibit improved performance over standard lanthanum carbonate tetrahydrate in phosphate binding studies. Lanthanum carbonate dihydrate is useful for the treatment of hyperphosphataemia in patients with renal failure. | 03-08-2012 |
| 20120064172 | BONE FILLING MATERIAL COMPRISING SINTERED TITANIUM DIOXIDE AND DEXTRIN AND METHOD FOR RECONSTRUCTING BONE DEFECTS USING THE SAME - A bone filling material comprising sintered titanium dioxide and dextrin and a method for reconstructing bone defects which comprises filling the bone defects in an animal with the bone filling material. The bone filling material of the invention has excellent cell compatibility, biocompatibility and shape-imparting property. | 03-15-2012 |
| 20120219637 | PHARMACEUTICAL COMPOSITIONS OF LANTHANUM CARBONATE AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to compact pharmaceutical compositions of lanthanum carbonate comprising diluents in an amount ranging from about 30% w/w to about 40% w/w of the composition. | 08-30-2012 |
| 20120282346 | BRIMONIDINE COMPOSITIONS FOR TREATING ERYTHEMA - The present invention is directed to a pharmaceutical composition including brimonidine tartrate in an amount from about 0.17 percent by weight to about 0.19 percent by weight in a pharmaceutically acceptable carrier such as a gel or cream. The invention also relates to a method of treating erythema in a patient with rosacea by administering the composition of the invention to the site of erythema on the skin of the patient. | 11-08-2012 |
| 20120328712 | CARBON MONOXIDE RELEASING RHENIUM COMPOUNDS FOR MEDICAL USE - The present invention relates to new rhenium compounds of formula (I) | 12-27-2012 |
| 20130004584 | ANTI-INFLAMMATORY, RADIOPROTECTIVE, AND LONGEVITY ENHANCING CAPABILITIES OF CERIUMOXIDE NANOPARTICLES - The present invention provides cerium oxide nanoparticles for use both in therapeutic compositions in vivo and in research in vitro. The cerium oxide nanoparticles are of known range of sizes having biological properties that are reproducible and beneficial. Pharmaceutical and other compositions are provided, as are methods of treatment. | 01-03-2013 |
| 20130071489 | METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier. | 03-21-2013 |
| 20130115308 | DOPED MATERIAL - A doped material comprises TiO | 05-09-2013 |
| 20130266663 | SOX9 INHIBITORS - Methods for treating a condition associated with proteoglycan production in a mammal are provided. The methods comprise the administration of at least one of a calmodulin antagonist, a transient receptor potential (TRP) channel inhibitor and a calmodulin-binding peptide to the mammal. | 10-10-2013 |
| 20130302439 | NEW USE OF FOOD COMPOSITIONS AND PRODUCTS COMPRISING OXIDES AND/OR HYDROXIDES - The subject matter of the invention relates to the use of a composition comprising at least one oxide and/or hydroxide insoluble in an aqueous environment, preferably selected from silicon dioxide (SlO2), titanium dioxide (TlO2), aluminium oxide (AI2O3) and aluminium hydroxide (Al(OH)3), magnesium oxide (MgO), to reduce absorption of the ethanol ingested through the consumption of alcoholic beverages. The invention also comprises the use of food products comprising these mixtures for the aforesaid use. | 11-14-2013 |
| 20130330416 | Styptic Storage and Delivery - Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium. | 12-12-2013 |
| 20130337083 | NANOCERIA FOR THE TREATMENT OF OXIDATIVE STRESS - A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury. | 12-19-2013 |
| 20130337084 | NANOCERIA WITH CITRIC ACID ADDITIVE - A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid, an oxidant, and water, is adjusted to a predetermined range of pH, held at temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. Dispersions of these biocompatible cerium oxide nanoparticles exhibit self-life well in excess of one year, and may be used to prevent and/or treat disease or injury, such as oxidative stress related diseases and events. | 12-19-2013 |
| 20140056992 | SUSPENSION OF NANOPARTICLES - A method for preparing suspension of inorganic nanoparticles is described herein. The method includes mixing a dispersing medium ( | 02-27-2014 |
| 20140099385 | INHIBITION OF FATTY ACID AND CHOLESTEROL UPTAKE BY CARBON MONOXIDE (CO) - An object of the present invention is to provide a composition for inhibiting fatty acid and cholesterol uptake in a living cell which is an inhibitor for fatty acid or cholesterol uptake by a living cell, comprising carbon monoxide (CO) or a compound capable of releasing CO in vivo. | 04-10-2014 |
| 20140113002 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 04-24-2014 |
| 20140193518 | KINASE INHIBITOR COMPOUNDS - The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer. | 07-10-2014 |
| 20140287060 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 09-25-2014 |
| 20140287061 | IN-SITU CROSS-LINKABLE POLYMERIC COMPOSITIONS AND METHODS THEREOF - A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition. | 09-25-2014 |
| 20140342016 | NON-INVASIVE REFRACTIVE TREATMENT USING NANOPARTICLES - Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye. | 11-20-2014 |
| 20140342017 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 11-20-2014 |
| 20150030695 | CAPSULE AND POWDER FORMULATIONS CONTAINING LANTHANUM COMPOUNDS - The present invention includes an oral pharmaceutical capsule comprising a shell, lanthanum carbonate or lanthanum carbonate hydrate, and a lubricant such as talc, wherein the shell encapsulates the lanthanum carbonate or its hydrate and the lubricant. Capsule shells comprise, for example, gelatin. The present invention also includes an oral pharmaceutical powder comprising lanthanum carbonate or lanthanum carbonate hydrate and a pharmaceutically acceptable excipient. The oral pharmaceutical capsules and powders of the present invention can be administered to treat a patient at risk of or suffering from hyperphosphatemia, at risk of or suffering from chronic kidney disease (CKD), at risk of or suffering from soft tissue calcification associated with CKD, or at risk of or suffering from secondary hyperparathyroidism. | 01-29-2015 |
| 20150140119 | METHOD FOR BONE TISSUE REGENERATION IN EXPERIMENTS - The invention relates to the treatment of different bone injuries, particularly fractures and fissure fractures, and can be used in medical and veterinary therapy and surgery. In order to reduce the time taken for bone tissue to regenerate at the site of damage or a defect and to reduce the time taken for the normal physiological functioning of an injured bone o be restored, a method is used for regenerating bone tissue by fixing fragments of the damaged bone with a plaster cast or a bandage made of a polymer material and introducing into the fracture zone an aqueous solution containing 1-hydroxyethylidene diphosphonic acid in an amount of (1.80-2.06) g/l, anhydrous calcium chloride in an amount of (1.44-2.22) g/l, gadolinium (III) nitrate hexahydrate in an amount of (0.3-0.40) g/l and dysprosium (III) chloride hexahydrate in an amount of (0.038-0.076) g/l, with a pH of (7.3-7.8), wherein, prior to being introduced into the fracture zone, the above solution is brought to a temperature of (30-100)° C., is held at this temperature for (1-48) hours and is then cooled to room temperature. As a result, there is a significant (20-25%) reduction in the time taken for bone tissue to regenerate at the injury site, irrespective of the type of animal which has sustained the injury. The above-mentioned solution for injection has low toxicity and good storage properties and can be kept for an extended period of time without loss of activity. | 05-21-2015 |
| 20150140120 | STABILIZED APTAMERS TO PLATELET DERIVED GROWTH FACTOR AND THEIR USE AS ONCOLOGY THERAPEUTICS - Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used one or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptarmers having one or more CpG motifs embedded therein or appended thereto. | 05-21-2015 |
| 20150352074 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY - Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described. | 12-10-2015 |
| 20150359820 | USE OF TUNGSTEN (VI) SALTS FOR THE TREATMENT OF FEMALE INFERTILITY IN NON-DIABETIC MAMMALS - The present invention comprises the use of a therapeutically effective amount of a tungsten (VI) salt with a pharmaceutically or veterinarily acceptable cationic group, or a solvate of said salt, for the preparation of a medicinal product for the treatment of female infertility in non-diabetic mammals. | 12-17-2015 |
| 20160008316 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | 01-14-2016 |
| 20160038537 | NEURONAL PROTECTION BY CERIUM OXIDE NANOPARTICLES - A method of treating a subject with elevated levels of peroxynitrite includes administering a therapeutically effective amount of cerium oxide nanoparticles to the subject, wherein the cerium oxide nanoparticles reduce the level of peroxynitrite in the subject. | 02-11-2016 |
| 20160040240 | CACNA1C ALLELE AND TREATMENT OF MOOD DISORDERS - Provided herein are methods of determining a treatment regimen for a subject with a mood disorder and methods of identifying a patient with a mood disorder as amenable to treatment with a calcium channel blocker (CCB). In exemplary embodiments, the methods comprise (a) analyzing a sample obtained from a subject with a mood disorder for the presence of allele [A] of CACNA1C, wherein allele [A] comprises the sequence of the polymorphic marker rs1006737. | 02-11-2016 |
| 20160101045 | NON-INVASIVE REFRACTIVE TREATMENT USING NANOPARTICLES - Embodiments of this invention generally relate to systems and methods for optical treatment and more particularly to non-invasive refractive treatment method based on sub wavelength particle implantation. In an embodiment, a method for optical treatment identifies an optical aberration of an eye, determines a dopant delivery device configuration in response to the optical aberration of the eye, wherein the determined dopant delivery device is configured to impose a desired correction to the eye to mitigate the identified optical aberration of the eye by applying a doping pattern to the eye so as to locally change a refractive index of the eye. | 04-14-2016 |
| 20160143987 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS - The present invention comprises methods of treating an infection using a pharmaceutical composition comprising an active ingredient selected from Table 1. In some aspects, the infection can be caused by one or more pathogens, including fungal pathogens. For example, the infection may be Valley Fever. | 05-26-2016 |
| 20160158282 | TUNGSTATE TREATMENT OF THE DYSBIOSIS ASSOCIATED WITH GASTROINTESTINAL INFLAMMATION - The present invention provides compositions of therapeutic agents and methods of use for reducing and/or treating gastrointestinal inflammation. In particular aspects, the tungstate salts described herein and pharmaceutical compositions thereof inhibit the activity of one or a plurality of anaerobic respiratory enzymes in facultative anaerobic bacteria such as, for example, Enterobacteriaceae, that can exacerbate inflammation. In particular embodiments, the present invention provides compositions of therapeutic agents for treating gastrointestinal inflammation, as well as methods for treating or preventing gut microbial imbalance due to an increase in the abundance of intestinal Enterobacteriaceae. | 06-09-2016 |
| 20160375055 | LANTHANUM CARBONATE COMPOSITIONS - The invention relates to stable oral pharmaceutical compositions comprising lanthanum carbonate compounds and pharmaceutically acceptable excipients. The compositions of the present invention are formulated without the use of flow aids or lubricants. The compositions of the present invention have physical properties & flowability indicators comparable to that of the powders containing flow aids or lubricants and these compositions can be filled in sachets without any difficulty. | 12-29-2016 |
